Metrics as of 10/14/2026, 08:04 AM (Berlin time), refresh in progress.
Milestone Scientific Inc.
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets.…
1D
-2.3%
1W
-7.4%
1M
-23.4%
6M
+16.4%
YTD
+24.5%
1Y
-36.9%
2Y
-60.9%
5Y
-84.3%
10Y
-82.1%
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~37% weaker price swings than usual
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.00
MEDIAN
US$1.00
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 20/11/2025
P/E
-7.13
P/B
9.12
EV/EBITDA
-7.31
RETURN ON EQUITY
-30.5%
NET MARGIN
-37.3%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
79.8%
FLOAT SHARES
70,621,314
AVG. DAILY VOLUME (30D)
89,635
Milestone Scientific Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Eric C. Hines, the company employs around 15 people.
The IPO was on 03/11/1995; the stock trades on AMEX under the ticker MLSS.
1 analysts rate the stock, the consensus is Buy (as of 20/11/2025).
The average price target is US$1.00, ranging from US$1.00 to US$1.00, with a median of US$1.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -37% stronger than usual.
No, Milestone Scientific currently does not pay a dividend.
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
Clicking "Analyze stock" lets five strategies assess Milestone Scientific against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.